Winning its second FDA approval this year, Boehringer Ingelheim's oral drug Jascayd is now cleared for use in the U.S. by ...

Columnist Samuel Kirton talks with the Pulmonary Fibrosis Foundation's Amy Hajari Case, MD, about the Accelerate Research ...

Musicians who play wind instruments are being warned of a potential hazard doctors have dubbed “bagpipe lung” — after a case study was published of a man who died of a lung condition known as ...

The U.S. Food and Drug Administration (FDA) recently granted orphan drug designation to Calluna Pharma‘s CAL101 as a potential treatment for idiopathic pulmonary fibrosis (IPF). This designation is ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Families will gather this week to celebrate Thanksgiving here in the U.S. But how do you safely navigate a large family gathering when colds, the flu, and COVID-19 are all circulating? After I ...

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...

Building on positive Phase 2 data, Puretech Health plans to launch a Phase 3 trial in the coming months to further test its experimental oral therapy deupirfenidone (LYT-100) in people with idiopathic ...

Pulmonary fibrosis (PF) is a serious lung disease characterized by lung inflammation and fibrosis, or scarring. Scar tissue makes it harder for lungs to expand and also impairs their ability to take ...

Blocking fatty acid synthase (FASN), an enzyme responsible for fatty acid production in cells, reduced the signs of induced idiopathic pulmonary fibrosis (IPF) in mice, according to a study ...

Treatment with Ofev (nintedanib) can significantly extend the survival of patients with idiopathic pulmonary fibrosis (IPF), an analysis of pooled data from six clinical trials shows. The analyis, ...

A University of Colorado professor has won the 2024 Alton Ochsner Award Relating Smoking and Disease for his work into how genetic and environmental factors, including smoking, contribute to a ...